Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2025

TCT 1040: Analyzing Value of Care in Venous Thromboembolism Management

Presenter: Alexandra So

October 27, 2025

Presentation TCT 2025

TCT 1685: Multivessel STEMI From Left Ventricular Thromboembolism in a Young Patient With Titin Gene Mutation and Myocarditis

Presenter: Afaq Motiwala

October 25, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

L.A. McKeown

June 17, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

L.A. McKeown

February 14, 2025

News Daily News

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Yael L. Maxwell

January 15, 2025

Advertisement

TCT 1040: Analyzing Value of Care in Venous Thromboembolism Management

TCT 1685: Multivessel STEMI From Left Ventricular Thromboembolism in a Young Patient With Titin Gene Mutation and Myocarditis

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

What’s Going to Be Hot at ACC 2025?

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content